t is made available under a	CC-BY 4.0	) International	license.
-----------------------------	-----------	-----------------	----------

1 2 3	Polygenic risk scores for the predicti based prospective cohort study	on of common cancers in East Asians: A population-		
4	Peh Joo Ho <sup>1, 2, 3</sup>	hopj@gis.a-star.edu.sg		
5 6 7	lain Bee Huat <b>Tan</b> <sup>1,4,5</sup>	iain.tan.b.h@singhealth.com.sg		
8 9	Dawn Qingqing Chong 5,6	dawn.chong.q.q@singhealth.com.sg		
10 11	Chiea Chuen <b>Khor</b> <sup>1</sup>	khorcc@gis.a-star.edu.sg		
12 13	Jian-Min <b>Yuan</b> <sup>7, 8</sup>	yuanj@upmc.edu		
14 15	Woon-Puay <b>Koh</b> <sup>9, 10</sup>	kohwp@nus.edu.sg		
16 17	Rajkumar <b>Dorajoo</b> <sup>1, #</sup>	dorajoor@gis.a-star.edu.sg		
18 19	Jingmei Li <sup>1, 3, #</sup>	lijm1@gis.a-star.edu.sg		
20 21 22 22 22 22 22 22 22 22 22 22 22 22	<ul> <li><sup>2</sup> Saw Swee Hock School of Public Heal Health System, Singapore</li> <li><sup>3</sup> Department of Surgery, Yong Loo Lin S Singapore</li> <li><sup>4</sup> Program in Cancer and Stem Cell Biol Singapore</li> <li><sup>5</sup> Division of Medical Oncology, National</li> <li><sup>6</sup> Duke-NUS Medical School Singapore, UPMC Hillman Cancer Center, Pittsbu</li> <li><sup>8</sup> Department of Epidemiology, Universit PA, USA</li> <li><sup>9</sup> Healthy Longevity Translational Resea University of Singapore, Singapore</li> <li><sup>10</sup> Singapore Institute for Clinical Science Singapore 117609, Singapore</li> <li>#Correspondence to: Dr Jingmei Li, Genome Institute of Singa 138672, Singapore. Tel: (65) 6808 8312</li> </ul>	Singapore rgh, Pennsylvania, USA ry of Pittsburgh Graduate School of Public Health, Pittsburgh, arch Programme; Yong Loo Lin School of Medicine, National es, Agency for Science Technology and Research (A*STAR), apore, 60 Biopolis Street, Genome, #02-01, Singapore 2; Email: <u>lijm1@gis.a-star.edu.sg</u> of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore		
54 55 56				
57				

It is made available under a CC-BY 4.0 International license .

58	
20	ABSTRACT
00	ADVIIVAVI

59 Background

- 60 To evaluate the utility of polygenic risk scores (PRS) in identifying high-risk individuals, different
- 61 publicly available PRS for breast (n=65), prostate (n=26), colorectal (n=12) and lung cancers (n=7)
- 62 were examined in a prospective study of 21,694 Chinese adults.
- 63

64 Methods

- 65 We constructed PRS using weights curated in the online PGS Catalog. PRS performance was
- 66 evaluated by distribution, discrimination, predictive ability, and calibration. Hazard ratios (HR) and
- 67 corresponding confidence intervals [CI] of the common cancers after 20 years of follow-up were
- 68 estimated using Cox proportional hazard models for different levels of PRS.
- 69
- 70 Results
- A total of 495 breast, 308 prostate, 332 female-colorectal, 409 male-colorectal, 181 female-lung and
- 72 381 male-lung incident cancers were identified. The area under receiver operating characteristic curve
- for the best performing site-specific PRS were 0.61 (PGS000004, breast), 0.66 (PGS00586, prostate),
- 74 0.58 (PGS000148, female-colorectal), 0.60 (PGS000734, male-colorectal) and 0.55 (PGS000740,
- female-lung), and 0.55 (PGS000392, male-lung), respectively. Compared to the middle quintile,

76 individuals in the highest PRS quintile were 67% more likely to develop cancers of the breast,

- prostate, and colorectal. For lung cancer, the lowest PRS quintile was associated with 31-45%
- 78 decreased risk compared to the middle quintile. In contrast, the hazard ratios observed for quintiles 4
- 79 (female-lung: 0.91 [0.58-1.44]; male-lung: 1.01 [0.74-1.38]) and 5 (female-lung: 1.00 [0.64-1.56];
- 80 male-lung: 1.07 [0.79-1.45]) were not significantly different from that for the middle quintile.
- 81

82 Conclusions

- 83 Site-specific PRSs can stratify the risk of developing breast, prostate, and colorectal cancers in this
- 84 East Asian population. Appropriate correction factors may be required to improve calibration.
- 85
- 86 Funding

It is made available under a CC-BY 4.0 International license .

- 87 This work is supported by the National Research Foundation Singapore (NRF-NRFF2017-02),
- 88 PRECISION Health Research, Singapore (PRECISE) and the Agency for Science, Technology and
- 89 Research (A\*STAR). WP Koh was supported by National Medical Research Council, Singapore
- 90 (NMRC/CSA/0055/2013). CC Khor was supported by National Research Foundation Singapore (NRF-
- 91 NRFI2018-01). Rajkumar Dorajoo received a grant from the Agency for Science, Technology and
- 92 Research Career Development Award (A\*STAR CDA 202D8090), and from Ministry of Health
- 93 Healthy Longevity Catalyst Award (HLCA20Jan-0022).
- 94 The Singapore Chinese Health Study was supported by grants from the National Medical Research
- 95 Council, Singapore (NMRC/CIRG/1456/2016) and the U.S. National Institutes of Health [NIH] (R01
- 96 CA144034 and UM1 CA182876).
- 97

# 98 Keywords

99 Population-based cancer screening, polygenic risk score, cohort study, Asian, calibration

It is made available under a CC-BY 4.0 International license .

## 101 INTRODUCTION

Polygenic risk scores (PRS) for a range of health traits and conditions have been developed in recent years. These scores, which are based on summary statistics from genome-wide association studies (GWAS), can be used to stratify people depending on their genetic risk of acquiring various diseases, to improve screening and preventative interventions, as well as patient care [1, 2]. Precision risk assessment may help develop tailored screening strategies targeting individuals at higher risk of disease of interest [3].

108

109 The contributions of heritable genetic factors are different for different cancers. Twin studies 110 have highlighted statistically significant effects of heritable genetic risk factors for cancers of the 111 prostate, colorectal, and breast [4]. The amount of phenotypic variance explained by the common 112 genetic variants found by GWAS is also known to vary [5], suggesting that PRS derived from GWAS 113 findings may perform to varying degrees for different cancers.

114

115 The area under receiver operating characteristic curve (AUC) is an important discrimination 116 index for evaluating the performance of PRS. The greater the AUC, the better the discriminatory 117 ability to separate cases from non-cases. A value of 0.5 suggests that the tool is performing no better 118 than chance, while a value of 1 is obtained when cases and non-cases are perfectly separated. The 119 range of reported AUC associated with published PRS ranged from 0.584 to 0.678 for breast cancer 120 [6-12], 0.591 to 0.769 for prostate cancer [8, 10, 13], 0.609 to 0.708 for colorectal cancer [8, 10, 14, 121 15], and 0.52 to 0.846 for lung cancer [8, 10, 13, 16]. In a study by Jia et al looking at eight common 122 cancers in the UK Biobank population-based cohort study (n=400.812 participants of European 123 descent), the observed AUC ranged from 0.567 to 0.662 [10].

124

While prediction of individual cancer risks through PRS remains moderate, emerging data supports the use of PRS for population-based cancer risk stratification. In previous work, Ho et al examined the overlap of women identified to be at high risk of developing breast cancer based on family history for the disease, a non-genetic breast cancer risk prediction model, a breast cancer PRS, and carriership of rare pathogenic variants in established breast cancer predisposition genes [17]. The overlap of individuals found to be at elevated risk of developing breast cancer based on the genetic

It is made available under a CC-BY 4.0 International license .

131	and non-genetic models was low. PRS was also found to be able to identify high-risk individuals
132	among young women who were not yet eligible to attend mammography screening. The findings
133	suggest that a genetic tool that is feasible to be deployed for population-based screening may
134	complement current screening programs.
135	
136	Disparities in the genetic risk of cancer among various ancestry populations are poorly
137	understood. Ideally, selected genetic variants that make up PRS should be relevant to the population
138	being screened. The development of training datasets of PRS are dominated by samples of European
139	ancestry, resulting in ancestry bias and issues with transferability to other populations [2, 18]. The
140	mismatch between the ancestries of the GWAS samples and the target populations for PRS
141	application is a limiting factor [18]. In this study, we evaluated the utility of common PRS, curated in
142	the Polygenic Score (PGS) Catalog, in predicting the risk of the commonly diagnosed cancers with
143	high genetic predisposition (breast, prostate, colorectal, and lung) in a prospective cohort comprising
144	21,694 participants of East Asian descent in Singapore.
145	
146	METHODS
147	
148	Singapore Chinese Health Study (SCHS)
149	The Singapore Chinese Health Study (SCHS) is a population-based prospective cohort study
150	of ethnic Chinese men and women recruited between April 1993 and December 1998 [19].
151	Participants were 45–74 years old at recruitment and were restricted to the two major dialect groups
152	of Chinese adults in Singapore, who were the Hokkiens and the Cantonese that had originated from
153	Fujian and Guangdong provinces in Southern China, respectively. All our study participants were
154	residents of government housing flats, which were built to accommodate approximately 86% of the
155	resident population in Singapore during the enrolment period. A total of 63 257 individuals (35,298
156	women and 27,959 men) provided written informed consent [19]. The study was approved by the
157	Institutional Review Boards of the National University of Singapore, University of Pittsburgh, and the
158	Agency for Science, Technology and Research (A*STAR, reference number 2022-042). Written,

159 informed consent was obtained from all study participants.

It is made available under a CC-BY 4.0 International license .

### 161 Baseline

An in-person baseline interview was performed at recruitment to collect data on diet using a validated 165-item food frequency questionnaire, smoking, alcohol, physical activity, medical history, and menstrual and reproductive history from women.

165

166 Selection of common cancers

167 In Singapore, between 2015 and 2019, colorectal cancer, the most prevalent cancer in men, 168 accounted for nearly 17% of cancer diagnoses, while breast cancer, the most common cancer in 169 women, accounted for about three out of ten cancer diagnoses (Singapore Cancer Registry Annual 170 Report 2018). During this time, cancers of the breast, prostate, colorectal, and lung accounted for 171 approximately half of the total cancer diagnoses. These four most common cancers were selected for 172 inclusion in this study.

173A unique National Registration Identity Card (NRIC) number for every Singaporean enables174the compilation and linkage of data from national register data to the same individual [20].

175 Identification of incident cases of cancer was accomplished by record linkage of all surviving cohort

176 participants with the database of the nationwide Singapore Cancer Registry [20]. Cancers that

177 developed among SCHS participants were identified using International Classification of Diseases

178 (ICD) codes ICD-O-3 (breast: C50, prostate: C61, colorectal: C18, C19 and C20, lung: C34).

179

180 Follow-up

181 Death date was obtained by record linkage with the database Birth and Death Registry of 182 Singapore [20]. To date, only 47 (<1%) of the entire cohort participants were known to be lost to 183 follow-up due to migration out of Singapore, suggesting that the ascertainment of cancer and death 184 incidences among the cohort participants was virtually complete.

185

### 186 Genotyping and imputation

187 Between 1999 and 2004, a total of 28,346 subjects contributed blood samples. A total of
188 25,273 SCHS participants were genotyped between the years 2017 to 2018 with the Illumina Infinium

189 Global Screening Array (GSA) v1.0 and v2.0 [21].

It is made available under a CC-BY 4.0 International license .

190	Details on the sample quality control (QC) processes are previously described [21]. Briefly,
191	samples with a call rate of 95% or below (n=176) or heterozygosity extremes (>3 standard deviation,
192	n=236) were removed. Identity-by-state measurements were performed by pairwise comparisons of
193	samples to detect related samples (first and second degree). One sample from each identified pair
194	with the lower call rate was eliminated from further analysis (n=2,746). To identify any ethnic outliers,
195	principal component analysis (PCA) was used in conjunction with 1000 Genomes Project reference
196	populations and within the SCHS samples, which resulted in the further removal of 287 samples. Of
197	the 21,828 samples that passed genotyping quality control, 134 participants who were diagnosed with
198	cancer before recruitment or had missing cancer outcomes and were excluded from the study,
199	resulting in a final analytical dataset of 21,694 (Supplementary Figure 1).

200 Alleles for all SNPs were coded to the forward strand and mapped to hg19. SNP guality 201 control steps included the exclusion of sex-linked and mitochondrial variants, gross Hardy-Weinberg equilibrium (HWE) outliers ( $P < 1 \times 10^{-6}$ ), monomorphic SNPs or those with a minor allele frequency 202 203 (MAF) < 1.0%, and SNPs with low call-rates (<95.0%). We imputed for additional autosomal SNPs 204 using IMPUTE v2 [22] and with a two reference panel imputation approach by including 1) the 205 cosmopolitan 1000 Genomes reference panels (Phase 3, representing 2,504 samples) and 2) an 206 Asian panel comprising 4,810 Singaporeans (2,780 Chinese, 903 Malays, 1127 Indians) [21]. SNPs 207 with imputation quality score INFO < 0.8, MAF < 1.0%, or HWE P < 1 ×  $10^{-6}$ , as well as non-biallelic

208 SNPs were excluded.

## 209 Polygenic risk scores (PRS)

210 Published polygenic risk scores (PRS) were retrieved from The Polygenic Score (PGS) 211 Catalog, an open database of polygenic scores (retrieved on Feb 26, 2022) (Additional file 1 -212 Supplementary Table 1) [23]. Of the 2,166 PRS available in the resource, 1,706 PRS comprising 213 less than 100,000 predictors were downloaded. A total of 65, 26, 12, and 7 PRS were available for 214 breast, prostate, colorectal, and lung cancers, respectively. Additional file 1 - Supplementary Table 215 2 shows the number of individual variants comprising each PRS and proportion of variants missing in 216 the SCHS cohort. Individual PRS were calculated using the allelic scoring (-score sum) functions with 217 default parameters in PLINK (v1.90b5.2) [24].

218

It is made available under a CC-BY 4.0 International license .

## 219 PRS distribution

- Two-sided, two-sample t-tests with a type I error of 0.05 were used to examine whether there was a difference in the distribution of standardised PRS (subtraction of mean value followed by the division by the standard deviation) between site-specific cancer cases and non-cancer controls.
- 223

## 224 PRS discrimination

- Discrimination was quantified by the area under the receiver operating characteristic (ROC) curve (AUC), using logistic regression models, and their corresponding 95% CI. An AUC of 0.9–1.0 is considered excellent, 0.8–0.9 very good, 0.7–0.8 good, 0.6–0.7 sufficient, and 0.5–0.6 insufficient
- 228 [25].
- 229

# 230 Associations between PRS and risk of developing cancers

231 Subjects were classified into PRS percentile groups. Person-years of follow-up were 232 calculated for each subject from the date of enrolment to the date of cancer diagnosis, death, or 233 December 31, 2015 (the date of linkage with the Singapore Cancer Registry), whichever came first. 234 Follow-up time was censored at 20 years after recruitment. The associations between PRS quintiles 235 (where individuals ranked by PRS were categorised into guintiles, using the middle guintile [40 to 236 60%] as reference to reflect the average risk of the population) and the incidence of site-specific 237 cancers were investigated using Cox proportional hazards modelling to estimate hazard ratios (HR) 238 and corresponding 95% confidence intervals (CI), using time since recruitment as the time scale, and 239 adjusted for age at recruitment. Tests for trends were conducted using two-sided Wald tests with a 240 type I error of 0.05. Assumptions for proportional hazards were checked using the cox.zph() function 241 in the "survival" package in R.

242

HR and corresponding 95% CI were also estimated for every standard deviation (SD)
increase in PRS. Variables adjusted in the models included age at recruitment, dialect group (Hokkien
or Cantonese), highest level of education (no formal education, primary school, or secondary or
higher), body mass index (continuous, kg/m<sup>2</sup>), cigarette smoking (non-smoker, ex-smoker, current
smoker), alcohol consumption (never, weekly, daily), moderate physical activity (none, 1-3h/week,

It is made available under a CC-BY 4.0 International license .

≥3h/week), vigorous work/strenuous physical activity at least once a week (no or yes), and familial

249 history of cancer (no or yes).

250	
251	To estimate the HR for each individual, we applied the <i>predict()</i> function with option
252	<i>type="risk"</i> to the Cox model with PRS (standardised to mean 0 and variance 1) and age at
253	recruitment. The proportion of study participants in the cohort with a given relative risk of each site-
254	specific cancer (HR <sub>per SD increase in PRS</sub> = 1.5, 2.0, 2.5, and 3.0), and the percentage of at-risk individuals
255	(based on the respective HR cut-offs) that develop cancer in all site-specific cancers were estimated.
256	
257	PRS predictive ability
258	The five-year absolute risks of developing breast, prostate, colorectal, and lung cancers were
259	computed for PRS groups of increasing five percentiles over the follow-up period. Incidence (between
260	2013 to 2017) and mortality (the year 2016) statistics in Singapore (reported in [26] and [27],
261	respectively) were used for the absolute risk estimations.
262	
263	PRS calibration
264	Calibration was studied by comparing the expected proportion of cases in the five years after
265	recruitment to the observed proportion of cases that occurred in that five years, within each decile of
266	PRS. Linear regression of the ten points (pairs of expected and observed proportion) was used to
267	study the overall calibration. A curve close to the diagonal indicates that predicted cancer risks
268	correspond well to observed proportions. A slope above 1 implies that the model underestimates the
269	absolute risk. Conversely, a slope below 1 implies that the model overestimates the absolute risk.
270	
271	RESULTS
272	
273	Characteristics of the study population
274	Table 1 shows the characteristics of the 21,694 participants who were cancer-free at
275	recruitment. The median follow-up time for the cohort was 20 years (IQR: 18 to 22). As of December
276	2015, 495 women developed breast cancer, 308 men developed prostate, 774 (332 women and 409
277	men) colorectal cancer, and 562 (181 women and 381) lung cancer. The median age at recruitment

278 was 54 years (interguartile range [IQR]: 49 to 61). The median age at diagnosis was 65 years (IQR: 279 59-70) for female breast cancers, 72 years (IQR: 67 to 77) for prostate cancers, 71 years (IQR: 65 to 280 76) for male colorectal cancers, 71 years (IQR: 64 to 78) for female colorectal cancers, 74 years (IQR: 281 68 to 78) for male lung cancers and 74 years (IQR: 66 to 79) for female lung cancers. Sixteen percent 282 of the cohort (n=3,501) reported positive first-degree family history of any cancer at baseline 283 interview. 284 285 Overall, eight in ten participants (79%) reported an education level of primary school and 286 above. However, the proportion of females who did not receive an education (32%) was four times 287 higher compared to males (8%). Median BMI was 23 kg/m<sup>2</sup> in the overall cohort, as well as in sex 288 specific and site-specific subgroups. There were more non-smokers among females (93%) compared 289 to males (45%). Alcohol consumption was low among the participants, with 88% of the cohort 290 reported never or occasional drinking (79% male, 95% female). Three in four participants reported 291 regular engagement in moderate physical activity; 85% of the participants reported no participation in 292 higher levels of physical activity. 293 294 Lack of Asian representation in PRS development 295 Among PRS for breast (n=65), prostate (n=26), colorectal (n=12) and lung cancers (n=7) 296 examined, the reported source of variant associations or GWAS used to build PRS were from 297 predominantly European ancestry populations (Additional file 1 - Supplementary Table 2). Only one 298 PRS for breast cancer (PGS001778) and two PRS for colorectal cancer (PGS000802 and 299 PGS000734) were based on GWAS that included some non-European participants. For PRS 300 development training, all but two PRS were based on samples of non-European ancestry 301 (PGS000733 for prostate cancer and PGS000802 for colorectal cancer). No significant association 302 (P>0.05) was found between number of variants included in the various PRS evaluated for each 303 cancer and discriminatory ability (Additional file 1 - Supplementary Table 3). 304 305 **PRS** distribution

Figure 1 depicts the A) distribution, B) discrimination, C) predictive ability, and D) calibration
 of the best-performing PRS (based on AUC) (Additional file 1 - Supplementary table 3) for the four

It is made available under a CC-BY 4.0 International license .

308 cancers studied: breast (PGS000004), prostate (PGS00586), colorectal (female: PGS000148; male: 309 PGS000734), and lung (female: PGS000740; male: PGS000392). All PRS were normally distributed, 310 with a right shift observed in the distribution curves for cancer cases (Figure 1A). The mean value of 311 each site-specific cancer PRS was significantly higher in cancer patients compared to controls (Pt-312 test<0.00273). 313

314

## Associations between PRS and risk of developing cancers

315 During the follow-up period of 20 years, the risk of acquiring breast, colorectal, or lung cancer 316 increased significantly with higher PRS after adjusting for age at recruitment. Compared to the first

317 PRS quintile, individuals in the highest quintile were more likely to develop the four cancers studied.

318 The highest hazard ratio observed was for prostate cancer (4.72 [95%CI: 3.04 – 7.34]) and lowest for

319 male lung cancer (1.54 [1.10 – 2.16]), adjusted for age at recruitment (Additional file 1 -

320 Supplementary Table 4). Significant trends were found for the associations between PRS quintiles

321 and site-specific cancers (P-trend ranges from 7.30 x 10<sup>-17</sup> for prostate cancer to 0.029 for female lung

322 cancer, Additional file 1 - Supplementary Table 4).

323

324 Compared to the middle PRS guintile, individuals in the highest PRS guintile were more than 325 67% more likely to develop cancers of the breast, prostate, and colorectal (Table 2). Individuals in the 326 lowest PRS quintile were associated with a 30-65% reduction in risk of developing these cancers. For 327 lung cancer, the lowest PRS quintile was associated with 31-45% decreased risk compared to the 328 middle quintile. However, the hazard ratios observed for quintiles 4 (female: 0.91 [0.58 to 1.44]; male: 329 1.01 [0.74 to 1.38]) and 5 (female: 1.00 [0.64 to 1.56]; male: 1.07 [0.79 to 1.45]) were not significantly 330 different when compared to the middle guintile.

331

332 Every SD increase in PRS is associated with 35-73% elevated risks of breast, prostate and 333 colorectal cancers (P<2.19 x 10<sup>-7</sup>, **Table 3**). The increased risk for female and male lung cancer was lower than the other three cancers (HR<sub>female</sub>: 1.17 [1.01 to 1.36], p=4.07 x 10<sup>-2</sup>; HR<sub>male</sub>: 1.17 [1.06 to 334 1.29],  $p=1.52 \times 10^{-3}$ ). Age at recruitment is significantly associated with elevated risks of developing all 335 336 cancers, with the exception of female breast cancer (HR: 1.00 [0.99 to 1.02], p=0.571). Highest 337 education level and BMI were positively correlated with breast cancer risk. Smoking was significantly

It is made available under a CC-BY 4.0 International license .

338 associated with a ~30% reduction in risk of prostate cancer, but increased the risk of lung cancer by 339 approximately two- and five-fold for past and current smokers, compared to non-smokers. 340 respectively. Alcohol consumption increased the risk of both female and male colorectal cancer by 341 approximately 60% but was only significant for male colorectal cancer. Family history of cancer was 342 only significantly associated with an increased risk for prostate cancer (HR: 1.61 [1.22 to 2.13], 343  $p=7.59 \times 10^{-4}$ ). 344 345 Number of cancers that developed within PRS at-risk groups 346 Modelling (Cox proportional hazards) the risk of developing cancer using standardized PRS 347 and accounting for age at recruitment, 14-23% of participants were at a greater than 1.5 risk of 348 developing prostate (23%), female breast (14%) and male colorectal cancer (14%) (Table 4). The 349 proportions were lower for female colorectal (6%) and lung cancer (1%). The number of participants 350 who developed site-specific cancers in the at-risk group represented 42%, 25%, 22%, 11%, and 1% 351 for prostate, female breast, male colorectal, female colorectal, and lung cancers, respectively. Among 352 1,674 women who were associated with HR>1.5 based on per standard deviation increase of PRS, 353 115 breast cancers (6.9%) developed during the follow-up. This proportion is nearly twice that of 354 women not identified to be at high risk (380/10,410, 3.7%). Among 2,220 men who were associated 355 with HR>1.5 based on per standard deviation increase of PRS, 120 prostate cancers (5.4%) 356 developed during the follow-up. This proportion is over twice that of men not identified to be at high 357 risk (118/7,390, 2.5%). 358 359 When age at recruitment was included in the models, 14-44% of the participants were at a 360 greater than 1.5 risk of developing the various cancers. The number of participants who developed

362 the participants were at a greater than 1.5 risk of developing the various cancers. The number of

site-specific cancers in the at-risk group increased to 24-55%. In the fully adjusted models, 18-58%

363 participants who developed site-specific cancers in the at-risk group increased further to 32-74%.

364

361

All Cox models presented in Tables 2, 3 and 4 did not violate the proportionality assumption
for the PRS studied (p-values of *cox-zph()* for PRS were >0.05).

367

It is made available under a CC-BY 4.0 International license .

## 368 PRS discriminatory ability

- 369 The highest AUC obtained from logistic models was observed for prostate cancer (0.66, 95%
- 370 CI: [0.62 to 0.69]), followed by female breast cancer (0.61 [0.58 to 0.63]), male colorectal cancer
- 371 (0.60, 95% CI = 0.58 to 0.63), female colorectal cancer (0.58 [0.54 to 0.61]), male lung cancer (0.55
- 372 [0.52 to 0.58]) and female lung cancer (0.55 [0.50 to 0.59]) (Figure 1B).
- 373

#### 374 PRS predictive ability

- 375 In terms of the five-year absolute risk of developing site-specific cancers, the largest
- 376 difference between the highest and lowest PRS categories was observed for prostate cancer,
- 377 followed by breast cancer (Figure 1C). A separation of the absolute risk curves was observed for
- 378 female breast cancer already at age 30 years. For prostate cancer, the separation of curves was
- observed only after age 50 years. Slight separation of the curves began after 50 years of age for
- 380 colorectal and lung cancer.

381

## 382 PRS calibration

In general, predicted risks for the higher PRS categories did not correspond well to the
 observed proportions for female breast, prostate, and female lung cancers (Figure 1D); in particular,
 predicted risks were overestimated for the higher risk categories. Overestimation of risk was observed
 for all PRS categories for male lung cancer. In contrast, predicted risks were underestimated for both
 female and male colorectal cancers.

388

## 389 DISCUSSION

390

Precision prevention in oncology is based on the idea that an individual's risk, which is influenced by genetics, environment, and lifestyle factors, is linked to the amount of benefit achieved through cancer screening [28]. Risk stratification for cancer screening can be used in this framework to identify and recommend screening for persons with a high enough cancer risk that the benefits outweigh the risks. Several PRS prediction models have been established for site-specific cancers, each with its own set of strengths and limitations, and different risk models may produce different results for the same individual.

It is made available under a CC-BY 4.0 International license .

In an increasingly inclusive world, genetic studies fall short on diversity. According to a 2009
study, an overwhelming 96% of people who took part in genome-wide association studies (GWAS)
were of European ancestry [29]. GWAS results are the backbone on which PRS is developed. A
concern raised was that, without representation from a broader spectrum of populations, genomic
medicine may be limited to benefitting "a privileged few" [30].

403

Genetic studies in 2016 showed that the proportion of people not of European ancestry included in GWAS has increased to approximately 20% [30]. Most of this rise can be attributed to more research on Asian ancestry communities in Asia [30]. With increasing interest worldwide in using a risk-based approach to screening programs over the current age-based paradigm, this progress raises questions on whether selected established PRS shown to perform well in Europeanbased populations has equal utility in Asians. Nonetheless, as our results show, most of the populations from which PRS were developed are still predominantly of European ancestry.

411

412 In accordance with published Polygenic Risk Score Reporting Standards, we reported PRS 413 distribution, discrimination, predictive ability, and calibration for each of the four common cancers 414 studied [31]. Our results show that cancer cases were associated with higher PRS compared to non-415 cancer controls. In the age-adjusted models, a constant trend between PRS percentile rank and 416 observed cancer risk in our study population supports the validity of PRS for breast, prostate, and 417 colorectal cancers, but not for lung cancer. The best-performing PRS for female breast cancer was 418 able to stratify women into distinct bands of breast cancer risk at an earlier age, and across all ages, 419 suggesting that it could be a useful prediction tool in risk-based breast cancer screening in 420 combination with other risk factors specific to breast cancer [17]. This PRS has been incorporated into 421 a pilot risk-based breast cancer screening study in a comparable study population [32]. The best 422 performing PRS for prostate and male colorectal cancers in this study appeared to exhibit sufficient 423 discriminatory ability and predictive value, especially for older participants.

424

PRS may be of limited use in predicting female colorectal and female/male lung cancer. The
least predictive value was in lung cancer, which could be related to the higher prevalence of EGFR
mutant lung cancer which has an Asian predilection, thus less amenable to PRS developed in

It is made available under a CC-BY 4.0 International license .

428 Caucasian population [33]. For these patients <10% of population were identified with >1.5 HR of
429 developing incident cancers.

430

431 There is room for improvement in the discriminatory ability of PRS [34]. As noted by Lambert 432 et al in a review, a wider divergence between the average scores of cases and non-cases (quantified 433 by AUC) and associated effect sizes (odds ratio and standard deviation) is expected when PRS 434 explains more of the heredity for each trait [2]. Larger GWAS sample sizes of appropriate ancestries 435 and the inclusion of rarer genetic variants, obtained through other methods such as whole-genome 436 sequencing, would likely be required to boost explained heritability [2]. In addition, group-wise 437 estimates, which arbitrarily classify the top 10%, 5%, or 1% of samples as the at-risk group, are not 438 optimal for decisions at the individual level [34]. Emerging new methodologies that estimate 439 probability values for hypothetically assigning an individual as at risk or not at risk, thus providing 440 individuals with more clarity, may help to overcome this limitation [35]. At this point, PRS may not 441 have yet reached the standards as a clinical tool by itself. However, it is still helpful in guiding 442 screening decisions and supplementing established protocols [1].

443

444 As highlighted by Wei et al, the reliability of score values is necessary for application at the 445 individual level [36]. Even when the PRS have adequate discrimination, estimated risks can be 446 unreliable [37]. Our results show that cancer risk estimates based on PRS developed using 447 populations of European ancestry are not optimally calibrated for our Asian study population. Poorly 448 calibrated PRS can be misleading and have clinical repercussions [37, 38]. Underestimation of risk 449 may result in a false sense of security. Overestimation of risk may cause unnecessary anxiety, 450 misguided interventions, and overtreatment. In a population-wide screening setting, however, where 451 the return of PRS results can be designed such that only high-risk individuals are highlighted, 452 underestimation of risk may be less of an issue. Arguably, with parallel input from other risk factors 453 and evaluation by healthcare specialists, the overestimation of risk that results in a higher number of 454 at-risk individuals identified may increase the number of cancers potentially detected early. 455 Nonetheless, suitable correction factors will be required to ensure the reliability of PRS prior to clinical 456 implementation.

457

It is made available under a CC-BY 4.0 International license .

458 While the study population used in this analysis comprises less than a thousand cases of the 459 most common cancers examined, the Singapore Chinese Health Study, established between April 460 1993 and December 1998, is one of the largest population-based Asian cohorts in the world with high-461 quality prospective data on exposure and comprehensive capture of morbidity and mortality. All 462 cancer cases are incident cases diagnosed over three decades of follow-up. This is one of the best 463 resources to evaluate the utility of PRS in a prospective manner. The findings open a window in our 464 current understanding of which PRS is relevant and ready to be deployed in risk-based cancer 465 screening studies.

466

467 Ethnic representation in PRS model development, PRS validation, limited discriminative 468 ability in the general population, ill calibration, insufficient healthcare professional and patient 469 education, and healthcare system integration are all hurdles that must be crossed before PRS can be 470 implemented responsibly as a public health instrument [39, 40]. Importantly, genetic literacy will be a 471 critical prerequisite for the successful implementation of PRS in population-based health screening. It 472 is pivotal that uncertainty associated with risk estimates derived from PRS is communicated clearly 473 [1]. In addition, an individual flagged to be at high risk of developing cancer may be unaware of the 474 range of surveillance options available [41]. In a commentary evaluating the "right not to know" in 475 genomics research by Gold and Green, it was noted that among those who chose not to have their 476 results returned, nearly half of them changed their minds after an education intervention [42].

477

While nationwide screening programs have helped to raise cancer awareness, there is still a
need to improve the effectiveness and efficiency of cancer screening in Asian countries such as
Singapore, given the steadily rising incidence rates. Despite the challenges, a risk-based screening
strategy that includes the use of PRS should be actively examined for research and implementation.

482

#### 483 **DECLARATIONS**

### 484 Ethics approval and consent to participate

485 The study was approved by the institutional review boards of the University of Southern California, the

486 National University of Singapore, and the Agency for Science, Technology and Research (A\*STAR,

487 reference number 2022-042). Written, informed consent was obtained from all study participants.

It is made available under a CC-BY 4.0 International license .

488	
489	Consent for publication
490	Not applicable.
491	
492	Availability of data and materials
493	All polygenic risk scores used in this study are publicly available in the PGS Catalog
494	(https://www.pgscatalog.org).
495	
496	The data that support the findings of our study are available from the corresponding authors of the
497	study upon reasonable request (Dr Rajkumar s/o Dorajoo, dorajoor@gis.a-star.edu.sg and Dr Jingmei
498	Li, lijm1@gis.a-star.edu.sg). More information regarding the data access to SCHS can be found at:
499	https://sph.nus.edu.sg/research/cohort-schs/. The data are not publicly available due to Singapore
500	laws.
501	
502	Source Data 1 contain the numerical data used to generate the figure 1.
503	The code for the study is uploaded as Source Code 1.
504	
505	
506	Competing interests
507	The authors have declared that no competing interests exist.
508	
509	Authors' contributions
510	Conception or design of work: Jingmei Li, Peh Joo Ho, Rajkumar s/o Dorajoo
511	Acquisition of resources for the generation of data, identification of outcomes via linkage and
512	supervision for the collection of data: Woon Puay Koh (PI of the Singapore Chinese Health Study)
513	Data acquisition: Jingmei Li, Rajkumar s/o Dorajoo, Chiea Chuen Khor, Woon Puay Koh, Jian-Min
514	Yuan
515	Interpretation of data: Jingmei Li, Peh Joo Ho, Rajkumar s/o Dorajoo, lain Bee Huat Tan
516	Drafting of manuscript: Jingmei Li, Peh Joo Ho, Rajkumar s/o Dorajoo
517	Manuscript approval: All authors

It is made available under a CC-BY 4.0 International license .

5	1	8
J		o

- 519 All authors agreed both to be personally accountable for the author's own contributions and to ensure
- 520 that questions related to the accuracy or integrity of any part of the work, even ones in which the
- 521 author was not personally involved, are appropriately investigated, resolved, and the resolution
- 522 documented in the literature.
- 523

## 524 Acknowledgments

- 525 We thank the Singapore Cancer Registry for the identification of incident cancer cases among
- 526 participants of the Singapore Chinese Health Study and Siew-Hong Low of the National University of
- 527 Singapore for supervising the fieldwork of the Singapore Chinese Health Study.
- 528
- 529
- 530
- 531
- 532
- 533

534

535

536

537

538

539

540

. . •

Polygenic Risk Score Task Force of the International Common Disease A:

## 542 **REFERENCES**

1.

- 544 Responsible use of polygenic risk scores in the clinic: potential benefits, risks 545 and gaps. Nat Med 2021, 27(11):1876-1884. 546 2. Lambert SA, Abraham G, Inouye M: Towards clinical utility of polygenic risk 547 scores. Hum Mol Genet 2019, 28(R2):R133-R142. 548 Clift AK, Dodwell D, Lord S, Petrou S, Brady SM, Collins GS, Hippisley-Cox J: The 3. 549 current status of risk-stratified breast screening. Br J Cancer 2022, 126(4):533-550 550. 551 4. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala 552 E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation 553 of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N 554 Engl J Med 2000, 343(2):78-85. 555 Cano-Gamez E, Trynka G: From GWAS to Function: Using Functional Genomics 5. 556 to Identify the Mechanisms Underlying Complex Diseases. Front Genet 2020, 557 **11**:424. 558 6. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, 559 Wang Q, Bolla MK et al: Polygenic Risk Scores for Prediction of Breast Cancer 560 and Breast Cancer Subtypes. Am J Hum Genet 2019, 104(1):21-34. 561 7. Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, Li J, Ho PJ, Dennis J, Tyrer JP, 562 Bolla MK et al: European polygenic risk score for prediction of breast cancer 563 shows similar performance in Asian women. Nat Commun 2020, 11(1):3833. 564 8. Kachuri L, Graff RE, Smith-Byrne K, Meyers TJ, Rashkin SR, Ziv E, Witte JS, 565 Johansson M: Pan-cancer analysis demonstrates that integrating polygenic risk 566 scores with modifiable risk factors improves risk prediction. Nat Commun 2020, **11**(1):6084. 567 568 9. Du Z, Gao G, Adedokun B, Ahearn T, Lunetta KL, Zirpoli G, Troester MA, Ruiz-569 Narvaez EA, Haddad SA, PalChoudhury P et al: Evaluating Polygenic Risk Scores 570 for Breast Cancer in Women of African Ancestry. J Natl Cancer Inst 2021, 571 **113**(9):1168-1176. 572 10. Jia G, Lu Y, Wen W, Long J, Liu Y, Tao R, Li B, Denny JC, Shu XO, Zheng W: 573 Evaluating the Utility of Polygenic Risk Scores in Identifying High-Risk 574 Individuals for Eight Common Cancers. JNCI Cancer Spectr 2020. 4(3):pkaa021. 575 11. Lacaze P, Bakshi A, Riaz M, Orchard SG, Tiller J, Neumann JT, Carr PR, Joshi AD, 576 Cao Y, Warner ET et al: Genomic Risk Prediction for Breast Cancer in Older 577 Women. Cancers (Basel) 2021, 13(14). 578 12. Zhang X, Rice M, Tworoger SS, Rosner BA, Eliassen AH, Tamimi RM, Joshi AD, 579 Lindstrom S, Qian J, Colditz GA et al: Addition of a polygenic risk score, 580 mammographic density, and endogenous hormones to existing breast cancer 581 risk prediction models: A nested case-control study. PLoS Med 2018, 582 15(9):e1002644.
- Fritsche LG, Patil S, Beesley LJ, VandeHaar P, Salvatore M, Ma Y, Peng RB, Taliun
   D, Zhou X, Mukherjee B: Cancer PRSweb: An Online Repository with Polygenic
   Risk Scores for Major Cancer Traits and Their Evaluation in Two Independent
   Biobanks. Am J Hum Genet 2020, 107(5):815-836.
- 587 14. Gafni A, Dite GS, Spaeth Tuff E, Allman R, Hopper JL: Ability of known colorectal cancer susceptibility SNPs to predict colorectal cancer risk: A cohort study within the UK Biobank. *PLoS One* 2021, 16(9):e0251469.
- Archambault AN, Jeon J, Lin Y, Thomas M, Harrison TA, Bishop DT, Brenner H, Casey G, Chan AT, Chang-Claude J *et al*: Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study. J Natl Cancer Inst 2022.

594 595	16.	Hung RJ, Warkentin MT, Brhane Y, Chatterjee N, Christiani DC, Landi MT, Caporaso NE, Liu G, Johansson M, Albanes D <i>et al</i> : <b>Assessing Lung Cancer Absolute Risk</b>
596 597 598	17.	<b>Trajectory Based on a Polygenic Risk Model</b> . <i>Cancer Res</i> 2021, <b>81</b> (6):1607-1615. Ho PJ, Ho WK, Khng AJ, Yeoh YS, Tan BK, Tan EY, Lim GH, Tan SM, Tan VKM, Yip CH <i>et al</i> : <b>Overlap of high-risk individuals predicted by family history, and</b>
599 600	40	genetic and non-genetic breast cancer risk prediction models: implications for risk stratification. <i>BMC Med</i> 2022, <b>20</b> (1):150.
601 602	18.	Fritsche LG, Ma Y, Zhang D, Salvatore M, Lee S, Zhou X, Mukherjee B: <b>On cross-</b> ancestry cancer polygenic risk scores. <i>PLoS Genet</i> 2021, <b>17</b> (9):e1009670.
603 604	19.	Hankin JH, Stram DO, Arakawa K, Park S, Low SH, Lee HP, Yu MC: <b>Singapore</b> <b>Chinese Health Study: development, validation, and calibration of the</b>
605 606	20.	quantitative food frequency questionnaire. <i>Nutr Cancer</i> 2001, <b>39</b> (2):187-195. Emmanuel S: Quality assurance in medicine: research and evaluation activities
607 608 609	21.	towards quality control in Singapore. <i>Ann Acad Med Singap</i> 1993, <b>22</b> (2):129-133. Chang X, Gurung RL, Wang L, Jin A, Li Z, Wang R, Beckman KB, Adams-Haduch J, Meah WY, Sim KS <i>et al</i> : Low frequency variants associated with leukocyte
610 611		telomere length in the Singapore Chinese population. <i>Commun Biol</i> 2021, <b>4</b> (1):519.
612 613 614	22.	Marchini J, Howie B, Myers S, McVean G, Donnelly P: <b>A new multipoint method</b> <b>for genome-wide association studies by imputation of genotypes</b> . <i>Nat Genet</i> 2007, <b>39</b> (7):906-913.
615 616	23.	Lambert SÁ, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, McMahon A, Abraham G, Chapman M, Parkinson H <i>et al</i> : <b>The Polygenic Score Catalog as an open</b>
617 618		database for reproducibility and systematic evaluation. <i>Nat Genet</i> 2021, <b>53</b> (4):420-425.
619	24.	Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ: Second-
620 621		generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015, 4:7.
622 623	25.	Simundic AM: Measures of Diagnostic Accuracy: Basic Definitions. <i>EJIFCC</i> 2009, <b>19</b> (4):203-211.
624 625	26.	Singapore Cancer Registry 50th Anniversary Monograph (1968 – 2017) [https://www.nrdo.gov.sg/publications/cancer]
626 627	27.	Age-Specific Death Rates, Annual [https://www.tablebuilder.singstat.gov.sg/publicfacing/viewMultiTable.action]
628 629	28.	Roberts MC: Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine. JAMA Oncol 2018, 4(11):1484-1485.
630 631	29.	Need AC, Goldstein DB: Next generation disparities in human genomics: concerns and remedies. <i>Trends Genet</i> 2009, <b>25</b> (11):489-494.
632 633	30.	Popejoy AB, Fullerton SM: <b>Genomics is failing on diversity</b> . <i>Nature</i> 2016, <b>538</b> (7624):161-164.
634	31.	Wand H, Lambert SA, Tamburro C, Iacocca MA, O'Sullivan JW, Sillari C, Kullo IJ,
635 636		Rowley R, Dron JS, Brockman D <i>et al</i> : Improving reporting standards for polygenic scores in risk prediction studies. <i>Nature</i> 2021, 591(7849):211-219.
637 638	32.	Liu J, Ho PJ, Tan THL, Yeoh YS, Chew YJ, Mohamed Riza NK, Khng AJ, Goh SA, Wang Y, Oh HB <i>et al</i> : <b>BREAst screening Tailored for HEr (BREATHE)-A study</b>
639 640		protocol on personalised risk-based breast cancer screening programme. PLoS One 2022, <b>17</b> (3):e0265965.
641 642 643	33.	Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba, II, Fong KM, Lee H, Toyooka S, Shimizu N <i>et al</i> : <b>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers</b> . <i>J Natl Cancer</i>
644 645	34.	Inst 2005, 97(5):339-346. Lewis ACF, Green RC: Polygenic risk scores in the clinic: new perspectives
646		needed on familiar ethical issues. Genome Med 2021, 13(1):14.
647 648	35.	Sun J, Wang Y, Folkersen L, Borne Y, Amlien I, Buil A, Orho-Melander M, Borglum AD, Hougaard DM, Regeneron Genetics C <i>et al</i> : <b>Translating polygenic risk scores</b>

649		for clinical use by estimating the confidence bounds of risk prediction. Nat
650		Commun 2021, <b>12</b> (1):5276.
651	36.	Wei J, Shi Z, Na R, Resurreccion WK, Wang CH, Duggan D, Zheng SL, Hulick PJ,
652		Helfand BT, Xu J: Calibration of polygenic risk scores is required prior to
653		clinical implementation: results of three common cancers in UKB. J Med Genet
654		2022, <b>59</b> (3):243-247.
655	37.	Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW, Topic
656		Group 'Evaluating diagnostic t, prediction models' of the Si: Calibration: the
657		Achilles heel of predictive analytics. BMC Med 2019, 17(1):230.
658	38.	Van Calster B, Vickers AJ: Calibration of risk prediction models: impact on
659		decision-analytic performance. Med Decis Making 2015, 35(2):162-169.
660	39.	Lewis CM, Vassos E: Polygenic risk scores: from research tools to clinical
661		instruments. Genome Med 2020, <b>12</b> (1):44.
662	40.	Slunecka JL, van der Zee MD, Beck JJ, Johnson BN, Finnicum CT, Pool R, Hottenga
663		JJ, de Geus EJC, Ehli EA: Implementation and implications for polygenic risk
664		scores in healthcare. Hum Genomics 2021, 15(1):46.
665	41.	Gold NB, Green RC: Reevaluating the "right not to know" in genomics research.
666		Genet Med 2022, <b>24</b> (2):289-292.
667	42.	Schupmann W, Miner SA, Sullivan HK, Glover JR, Hall JE, Schurman SH, Berkman
668		BE: Exploring the motivations of research participants who chose not to learn
669		medically actionable secondary genetic findings about themselves. Genet Med
670		2021, <b>23</b> (12):2281-2288.
671		
672		

#### It is made available under a CC-BY 4.0 International license .

674 **Table 1.** Demographics of our study population by gender and cancer site. Demographics variables

675 were collected using structured questionnaire at recruitment. Family history for lung cancer was not

676 available. Information on cancer occurrence (number of cancer and age at cancer occurrence) was

677 obtained through linkage with the Singapore Cancer Registry in December 2015. Follow-up time was

678 calculated from age at recruitment. IQR: Interquartile range. 679

	Entire cohort Individuals who developed cancer				cancer				
		I Female		Breast	Prostate	Colorectal		Lung	
	All		Male	Female	Male	Female	Male	Female	Male
n	21694	12084	9610	495	308	332	409	181	381
Age at recruitment in years, median (IQR)	54 (49–61)	54 (48–60)	55 (49–62)	53 (48-59)	59 (54-64)	58 (52-64)	59 (52-65)	59 (55-64)	60 (55-64)
Number of cancers developed									
0 (did not develop cancer) 1	19633 (90)	11096 (92)	8537 (89) 1045 (11)	-	- 293 (95)	- 317 (95)	- 297 (05)	- 175 (07)	- 362 (95)
2	2013 (9) 48 (0)	968 (8) 20 (0)	28 (0)	476 (96) 19 (4)	15 (5)	15 (5)	387 (95) 22 (5)	175 (97) 6 (3)	19 (5)
Age at diagnosis among individuals who develop cancer(s) (earliest age for those with multiple cancers) in years, median (IQR)	70 (64-77)	68 (62-76)	72 (67-77)	65 (59-70)	72 (67-77)	71 (64-78)	71 (65-6)	74 (66-79)	74 (68-78)
Length of follow-up (longest follow-up									
for those with multiple cancers) in years, median (IQR)	20 (18- 22)	20 (18-22)	19 (17-21)	11 (6-16)	13 (9-17)	13 (8-17)	11 (7-16)	14 (9-17)	14 (10-17)
Dialect group (%)									
Hokkien	10663 (49)	6132 (51)	4531 (47)	260 (53)	153 (50)	185 (56)	164 (40)	95 (52)	162 (43)
Cantonese	11031 (51)	5952 (49)	5079 (53)	235 (47)	155 (50)	147 (44)	245 (60)	86 (48)	219 (57)
Highest education (%)									
No	4629 (21)	3878 (32)	751 (8)	128 (26)	20 (6)	123 (37)	46 (11)	85 (47)	57 (15)
Primary level Secondary or above	9760 (45) 7305 (34)	5082 (42) 3124 (26)	4678 (49) 4181 (44)	206 (42) 161 (33)	146 (47) 142 (46)	138 (42) 71 (21)	232 (57) 131 (32)	62 (34) 34 (19)	228 (60) 96 (25)
Body mass index in kg/m <sup>2</sup> , median (IQR)	23 (21-25)	23 (21-25)	23 (21-25)	23 (21-25)	23 (21-25)	23 (21-24)	23 (21-25)	23 (20-24)	23 (20-24)
Smoking status (%)									
Never	15553 (72)	11235 (93)	4318 (45)	472 (95)	166 (54)	296 (89)	153 (37)	129 (71)	63 (17)
Ex-smoker Current smoker	2374 (11) 3767 (17)	261 (2) 588 (5)	2113 (22) 3179 (33)	8 (2) 15 (3)	66 (21) 76 (25)	14 (4) 22 (7)	108 (26) 148 (36)	9 (5) 43 (24)	74 (19) 244 (64)
Number of cigarettes smoked (%)									
Does not smoke	15553 (72)	11235 (93)	4318 (45)	472 (95) 14 (3)	166 (54)	296 (89)	153 (37) 85 (21) 108 (26)	129 (71) 36 (20)	63 (17) 81 (21)
<12 13-22	2408 (11) 2344 (11)	581 (5) 206 (2)	1827 (19) 2138 (22)	6 (1) 3 (1)	54 (18) 53 (17)	26 (8) 9 (3)	108 (26)	15`(8)́	135 (35) 102 (27)
>=23	1389`(6)′	62 (1)	1327 (14)	3(1)	35 (11)	1 (0)	63 (15)	1 (1)	102 (27)
Alcohol consumption (%) Never/ occasionally	19079 (88)	11506 (95)	7573 (79)	470 (95)	253 (82)	315 (95)	303 (74)	174 (96)	296 (78)
Weekly	1885 (9) 730 (3)	437 (4) 141 (1)	1448 (15)	20 (4) 5 (1)	44 (14)	10 (3) 7 (2)	66 (16)	( )	49 (13)
Daily	730 (3)	141 (1)	589 (6)	5 (1)	11 (4)	7 (2)	40 (10)	5 (3) 2 (1)	36`(9)'
Moderate physical activity (%) No	16584 (76)	9446 (78)	7138 (74)	380 (77)	208 (68)	269 (81)	295 (72)	143 (79)	294 (77)
1 to 3 hours/week >= 3 hours/week	16584 (76) 3274 (15) 1836 (8)	9446 (78) 1679 (14) 959 (8)	7138 (74) 1595 (17) 877 (9)	380 (77) 69 (14) 46 (9)	62 (20) 38 (12)	269 (81) 43 (13) 20 (6)	68 (17) 46 (11)	143 (79) 23 (13) 15 (8)	294 (77) 53 (14) 34 (9)
	1030 (0)	909 (0)	077 (9)	40 (9)	30(12)	20 (0)	40(11)	15 (6)	34 (9)
Vigorous physical activity/ strenuous sports at least once a week (%)									
No	18467 (85)	11221 (93)	7246 (75)	452 (91)	239 (78)	311 (94)	342 (84)	175 (97)	314 (82)
Yes	3227 (15)	863 (7)	2364 (25)	43 (9)	69 (22)	21 (6)	67 (16)	6 (3)	67 (18)
Family history of any cancer in first degree relatives (%)									
No Yes	18193 (84) 3501 (16)	10141 (84) 1943 (16)	8052 (84) 1558 (16)	404 (82) 91 (18)	236 (77) 72 (23)	281 (85) 51 (15)	336 (82) 73 (18)	165 (91) 16 (9)	333 (87) 48 (13)

It is made available under a CC-BY 4.0 International license .

680	Table 2. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) associated with
681	polygenic risk score quintiles (Q) compared to the population median, using the Cox proportional
682	hazards model and censored at 20 years after recruitment. All models were adjusted for age at
683	recruitment.

Cancer site - gender	Q1	Q2	Q3	Q4	Q5
Breast – Female					
Number of cases	54	76	86	103	147
HR (95%CI)	0.60 (0.43 – 0.84)	0.84 (0.62 – 1.14)	1.00 (Referent)	1.19 (0.89 – 1.58)	1.67 (1.28 – 2.17)
Prostate – Male					
Number of cases	24	27	68	59	111
HR (95%CI)	0.35 (0.22 – 0.57)	0.42 (0.27 – 0.65)	1.00 (Referent)	0.89 (0.63 – 1.26)	1.67 (1.24 – 2.26)
Colorectal – Female					
Number of cases	37	63	51	74	85
HR (95%CI)	0.70 (0.46 – 1.07)	1.25 (0.87 – 1.81)	1.00 (Referent)	1.48 (1.04 – 2.12)	1.69 (1.19 – 2.39)
Colorectal – Male					
Number of cases	36	70	71	87	114
HR (95%CI)	0.51 (0.34 – 0.77)	1.00 (0.72 – 1.39)	1.00 (Referent)	1.29 (0.94 – 1.76)	1.67 (1.24 – 2.25)
Lung – Female					
Number of cases	22	33	39	35	39
HR (95%CI)	0.55 (0.32 – 0.92)	0.81 (0.51 – 1.28)	1.00 (Referent)	0.91 (0.58 – 1.44)	1.00 (0.64 – 1.56)
Lung – Male					
Number of cases	56	64	79	75	86
HR (95%CI)	0.69 (0.49 – 0.97)	0.80 (0.57 – 1.11)	1.00 (Referent)	1.01 (0.74 – 1.38)	1.07 (0.79 – 1.45)

685 **Table 3.** Associations between per standard deviation (SD) increase in site-specific polygenic risk scores and cancer occurrence. Hazard ratios (HR) and

686 corresponding 95% confidence intervals (CI) were estimated using Cox proportional hazard models, adjusted for age at recruitment, dialect group, highest

687 education attained, body mass index, smoking status, alcohol consumption, and physical activity. Follow-up time was censored at 20 years after recruitment.

688 Significant results are shown in bold.

	Cancer site											
	Breast		Prostate		Colorectal - female		Colorectal - male		Lung - female		Lung - male	
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Site-specific polygenic risk score, per SD increase	1.46 (1.33 – 1.59)	3.83E-16	1.73 (1.54 – 1.95)	2.31E-20	1.35 (1.20 – 1.51)	2.19E-07	1.44 (1.30 – 1.59)	5.41E-12	1.17 (1.01 – 1.36)	4.07E-02	1.17 (1.06 – 1.29)	2.52E-03 <del>⊐</del>
Age at recruitment, years	1.00 (0.99 – 1.02)	5.71E-01	1.08 (1.06 – 1.10)	9.37E-22	1.07 (1.05 – 1.09)	1.00E-16	1.06 (1.05 – 1.08)	9.53E-18	1.07 (1.05 – 1.10)	1.90E-10	1.09 (1.07 – 1.10)	2.54E-27 <sup>万</sup> ∃
Dialect group (Cantonese vs Hokkien)	0.90 (0.74 – 1.08)	2.47E-01	0.98 (0.77 – 1.23)	8.35E-01	0.80 (0.64 – 1.01)	6.47E-02	1.22 (0.99 – 1.50)	6.78E-02	0.92 (0.67 – 1.26)	5.97E-01	1.06 (0.86 – 1.31)	5.95E-01@
Highest education (Primary vs No)	1.21 (0.95 – 1.53)	1.25E-01	1.28 (0.79 – 2.08)	3.19E-01	1.08 (0.83 – 1.40)	5.73E-01	0.98 (0.70 – 1.37)	8.91E-01	0.83 (0.58 – 1.19)	3.14E-01	0.90 (0.66 – 1.22)	4.98E-01
Highest education (Secondary or above vs No)	1.54 (1.18 – 2.01)	1.55E-03	1.54 (0.93 – 2.53)	9.01E-02	1.06 (0.76 – 1.48)	7.41E-01	0.80 (0.55 – 1.16)	2.33E-01	1.09 (0.69 – 1.73)	7.18E-01	0.65 (0.46 – 0.93)	1.89E-02
Body mass index, kg/m <sup>2</sup>	1.04 (1.02 – 1.07)	9.12E-04	1.01 (0.98 – 1.05)	4.51E-01	0.99 (0.96 – 1.02)	5.42E-01	1.02 (0.98 – 1.05)	3.19E-01	0.97 (0.92 – 1.01)	1.57E-01	0.96 (0.93 – 1.00)	4.93E-02 de
Smoking status (Ex-smoker vs Non-smoker)	0.90 (0.44 – 1.82)	7.70E-01	0.71 (0.52 – 0.96)	2.42E-02	1.50 (0.85 – 2.64)	1.59E-01	1.17 (0.90 – 1.52)	2.36E-01	2.16 (1.04 – 4.48)	3.82E-02	1.98 (1.39 – 2.80)	1.32E-04
Smoking status (Current smoker vs Non- smoker)	0.84 (0.50 – 1.41)	4.99E-01	0.72 (0.54 – 0.97)	2.85E-02	1.12 (0.70 – 1.78)	6.36E-01	1.22 (0.96 – 1.56)	1.08E-01	5.71 (3.93 – 8.29)	4.81E-20	5.02 (3.74 – 6.74)	6.26E-27
Alcohol consumption (Weekly vs Never/ Occasionally)	1.04 (0.65 – 1.67)	8.68E-01	0.96 (0.68 – 1.36)	8.31E-01	0.76 (0.38 – 1.54)	4.45E-01	1.31 (1.00 – 1.73)	5.39E-02	0.72 (0.27 – 1.94)	5.12E-01	0.90 (0.66 – 1.23)	5
Alcohol consumption (Daily vs Never/ Occasionally)	0.73 (0.27 – 1.97)	5.39E-01	0.70 (0.38 – 1.29)	2.54E-01	1.60 (0.71 – 3.60)	2.58E-01	1.64 (1.15 – 2.34)	6.54E-03	0.67 (0.17 – 2.72)	5.76E-01	1.23 (0.87 – 1.76)	2.42E-01
Moderate physical activity (1-3 hours/week vs No)	0.98 (0.75 – 1.27)	8.61E-01	1.16 (0.87 – 1.56)	3.13E-01	0.89 (0.63 – 1.24)	4.81E-01	1.02 (0.78 – 1.35)	8.79E-01	1.01 (0.63 – 1.61)	9.62E-01	0.88 (0.65 – 1.20)	4.32E-01
Moderate physical activity (≥3 hours/week vs No)	1.18 (0.86 – 1.61)	3.03E-01	1.05 (0.72 – 1.54)	7.81E-01	0.60 (0.37 – 0.97)	3.57E-02	1.10 (0.80 – 1.52)	5.45E-01	0.95 (0.53 – 1.68)	8.52E-01	0.84 (0.57 – 1.22)	3.51E-01
Vigorous physical activity/ strenuous sports at least once a week (Yes vs No)	1.24 (0.90 – 1.70)	1.88E-01	1.09 (0.82 – 1.45)	5.65E-01	1.08 (0.67 – 1.72)	7.62E-01	0.75 (0.57 – 1.00)	5.06E-02	0.57 (0.23 – 1.40)	2.22E-01	0.94 (0.71 – 1.25)	6.77E-01
Family history (Yes vs No)	1.15 (0.91 – 1.45)	2.53E-01	1.61 (1.22 – 2.13)	7.59E-04	1.08 (0.79 – 1.48)	6.17E-01	1.24 (0.95 – 1.62)	1.09E-01	0.67 (0.40 – 1.13)	1.36E-01	0.96 (0.71 – 1.32)	8.15E-01

690 Table 4. Number of individuals estimated to have a hazard ratio (HR) associated with per standard deviation increase in site-specific polygenic risk score
 691 above the arbitrary threshold (1.5, 2.0, 2.5 and 3.0). To estimate the HR for each individual, we applied the *predict()* function with option *type="risk"* to the Cox
 692 model with PRS (standardised to mean 0 and variance 1) and age at recruitment.

693	

	HR ≥ 1.5		HR ≥ 2.0		HF	R≥ 2.5	HR ≥ 3.0		
– Cancer site - gender	<i>n</i> (% of study population)	Number who developed cancer (% of total cases)	<i>n</i> (% of study population)	Number who developed cancer (% of total cases)	<i>n</i> (% of total in SCHS)	Number who developed cancer (% of total cases)	<i>n</i> (% of total in SCHS)	Number who developed cancer (% of total cases)	
Effect of PRS alone									
Breast – female	1674 (14)	115 (25)	373 (3)	27 (6)	84 (1)	10 (2)	27 (0)	2 (0)	
Prostate – male	2220 (23)	120 (42)	981 (10)	61 (21)	439 (5)	32 (11)	210 (2)	19 (7)	
Colorectal – female	756 (6)	33 (11)	48 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	
Colorectal – male	1300 (14)	82 (22)	291 (3)	23 (6)	72 (1)	10 (3)	15 (0)	3 (1)	
Lung – female	73 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Lung – male	52 (1)	2 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Total – females	2326 (19)	148 (19)	418 (3)	27 (4)	84 (1)	10 (1)	27 (0)	2 (0)	
Total – males	3250 (34)	204 (20)	1240 (13)	84 (8)	509 (5)	42 (4)	224 (2)	22 (2)	
Adjusted for age at recru	itment								
Breast – female	1698 (14)	112 (24)	373 (3)	26 (6)	86 (1)	10 (2)	29 (0)	2 (0)	
Prostate – male	2854 (30)	158 (55)	1834 (19)	118 (41)	1192 (12)	83 (29)	817 (9)	63 (22)	
Colorectal – female	2887 (24)	138 (45)	1561 (13)	92 (30)	850 (7)	57 (18)	447 (4)	34 (11)	
Colorectal – male	2510 (26)	175 (46)	1443 (15)	119 (31)	832 (9)	71 (19)	476 (5)	39 (10)	
Lung – female	3279 (27)	91 (54)	2104 (17)	62 (37)	1360 (11)	42 (25)	925 (8)	29 (17)	
Lung – male	2732 (28)	177 (49)	1687 (18)	107 (30)	1035 (11)	73 (20)	653 (7)	41 (11)	
Total – females	4273 (35)	249 (33)	1903 (16)	118 (15)	933 (8)	67 (9)	476 (4)	36 (5)	
Total – males	4189 (44)	498 (50)	2821 (29)	336 (34)	1914 (20)	221 (22)	1324 (14)	140 (14)	
Fully adjusted for all cova	ariates								
Breast – female	2209 (18)	150 (32)	760 (6)	61 (13)	257 (2)	25 (5)	86 (1)	12 (3)	
Prostate – male	3000 (31)	179 (62)	1947 (20)	135 (47)	1319 (14)	105 (36)	956 (10)	75 (26)	
Colorectal – female	3006 (25)	143 (46)	1663 (14)	94 (30)	935 (8)	60 (19)	548 (5)	37 (12)	
Colorectal – male	2803 (29)	204 (54)	1666 (17)	134 (35)	1041 (11)	97 (26)	640 (7)	58 (15)	
Lung – female	3111 (26)	98 (58)	2027 (17)	78 (46)	1402 (12)	64 (38)	1062 (9)	59 (35)	
Lung – male	3572 (37)	265 (74)	2734 (28)	232 (64)	2134 (22)	206 (57)	1684 (18)	180 (50)	
Total – females	4783 (40)	291 (38)	2363 (20)	155 (20)	1181 (10)	85 (11)	633 (5)	49 (6)	
Total – males	5542 (58)	633 (63)	4191 (44)	492 (49)	3247 (34)	400 (40)	2547 (27)	307 (31)	

medRxiv preprint doi: https://doi.org/10.1101/2022.09.12.22279874; this version posted September 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license

### 694 Figure 1. Site-specific polygenic risk scores (PRS) performance assessment.

A) Distribution, B) discrimination, C) predictive ability and D) calibration for each of the four common cancers studied. Two-sided, two-sample t-tests with a type I error of 0.05 were used to examine

696 whether there was a difference in the distribution of standardised PRS (subtraction of mean value followed by the division by the standard deviation) between site-specific cancer cases and noncancer controls (A). The PRS showcased are the best-performing scores based on Area Under the Receiver Operator Characteristic Curve (AUC) values in the female and male populations, i)

698 unadjusted [solid line], and ii) adjusted for age at recruitment [dashed line] (B). Each colored line in the plots for predictive ability denotes a five percentile increase in the standardised PRS score in (C). Calibration calculated based on five-year absolute risk by PRS deciles in (D). A prediction tool is considered more accurate when the AUC is larger. An AUC of 0.9–1.0 is considered excellent,

700

701

0.8–0.9 very good, 0.7–0.8 good, 0.6–0.7 sufficient, 0.5–0.6 bad, and less than 0.5 considered not useful (PMID: 27683318).



It is made available under a CC-BY 4.0 International license

It is made available under a CC-BY 4.0 International license .

# 702 ADDITIONAL FILES

703 Additional File 1 - Supplementary tables.xlsx